Cerebral palsy (CP) is caused by a static lesion to the brain occurring in utero or up to the
first 2 years of life; it often manifests as musculoskeletal impairments and movement …

Botulinum toxin type A (BTXA) has been used for over 25 years in the management of
pediatric lower and upper limb hypertonia, with the first reports in 1993. The most common …

Botulinum Neurotoxin type-A (BoNT-A) injections are widely used as first-line spasticity
treatment in spastic cerebral palsy (SCP). Despite improved clinical outcomes, concerns …

Aim To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing
upper limb spasticity in children with cerebral palsy (CP). Method This was a double‐blind …

Spasticity, following the neurological disorder of cerebral palsy (CP), describes a
pathological condition, the central feature of which is involuntary and prolonged muscle …

Cerebral palsy (CP) is a chronic congenital disorder as the result of abnormal brain
development. Children suffering from CP often battle debilitating chronic spasticity, which …

Aim To understand the long‐term effects of comprehensive spasticity treatment, including
selective dorsal rhizotomy (SDR), on individuals with spastic cerebral palsy. Method This …

Children with spastic cerebral palsy (SCP) are often treated with intramuscular Botulinum
Neurotoxin type-A (BoNT-A). Recent studies demonstrated BoNT-A-induced muscle atrophy …

Background: The novel coronavirus infection (SARS-CoV-2) caused disruption of the
treatment and follow-up evaluations of children with cerebral palsy. Aim: The change in …

This review aims to determine the analgesic efficacy of botulinum toxin (BTX) for the
management of pain in children with cerebral palsy (CP). During July and August 2020, a …